FDA Issues Guidance for IRBs, Investigators and Sponsors


On August 27, 2013, the Food and Drug Administration (FDA) announced the availability of guidance entitled “Guidance for IRBs, Clinical Investigators, and Sponsors: IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed.”  The guidance is intended to assist institutional review boards (IRBs), clinical investigators, and sponsors involved in clinical investigations of FDA-regulated products in determining whether the proposed research satisfies the criteria for approval contained in 21 C.F.R. § 56.111, which requires that risks to subjects are minimized and reasonable in relation to the anticipated benefit to such subjects. 

The guidance, which primarily consists of a compilation of recommendations in previously issued FDA guidance documents, addresses the IRB’s role in reviewing (1) the qualifications of clinical investigators, (2) the adequacy of the research sites, and (3) the determination of whether an IND/IDE is required.  The guidance does not operate to bind the FDA or the public.

The August 2013 publication finalizes the draft guidance dated November 2012 and replaces FDA guidance question 56 in the publication entitled, “Institutional Review Boards Frequently Asked Questions – Information Sheet – Guidance for Institutional Review Boards and Clinical Investigators.”  The public may submit written or electronic comments on the guidance at any time. 

The guidance is available here, and the FDA notice is available here.

Reporter, Juliet M. McBride, Houston, +1 713 276 7448, jmcbride@kslaw.com.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© King & Spalding | Attorney Advertising

Written by:


King & Spalding on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.